THDB(SH:600867) Zhong Zheng Wang·2026-02-27 03:05Group 1 - The core viewpoint of the news is that Tonghua Dongbao has signed a commercialization cooperation agreement with Huisheng Bio, aiming to enhance their presence in the diabetes treatment sector through resource complementarity and collaborative development [1][2]. - The agreement grants Tonghua Dongbao exclusive commercialization rights for Huisheng Bio's insulin products in mainland China, specifically the biosimilar insulin injections, which are expected to improve the accessibility of diabetes treatments [2][3]. - Tonghua Dongbao, as a leading domestic insulin manufacturer, has a strong market foundation and a mature commercialization system, which positions it well to rapidly promote and distribute the new products [3]. Group 2 - The collaboration is expected to enrich Tonghua Dongbao's product matrix in the endocrine metabolism field and strengthen its competitive edge in diabetes treatment, contributing to sustainable long-term growth [1][2]. - The partnership will leverage both companies' strengths, with Tonghua Dongbao focusing on market promotion and clinical application, while Huisheng Bio will enhance its R&D and technical support for stable product supply [3].